FibroBiologics (NASDAQ:FBLG) Announces Quarterly Earnings Results

FibroBiologics (NASDAQ:FBLG – Get Free Report) announced its earnings results on Monday. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.25, FiscalAI reports.

FibroBiologics Price Performance

FBLG stock traded down $0.02 during midday trading on Monday, hitting $0.90. The company’s stock had a trading volume of 97,460 shares, compared to its average volume of 230,361. The company’s fifty day moving average price is $1.18 and its 200 day moving average price is $2.13. FibroBiologics has a twelve month low of $0.62 and a twelve month high of $9.60. The stock has a market capitalization of $6.01 million, a P/E ratio of -0.17 and a beta of 1.81.

Analyst Ratings Changes

Several research analysts have recently weighed in on FBLG shares. Deutsche Bank cut shares of FibroBiologics to an “underperform” rating in a report on Tuesday, August 4th. HC Wainwright restated a “buy” rating and set a $6.00 price objective (down from $8.00) on shares of FibroBiologics in a report on Tuesday, August 4th. Wall Street Zen raised shares of FibroBiologics to a “hold” rating in a research report on Saturday, October 10th. Finally, Weiss Ratings raised shares of FibroBiologics from a “sell (e)” rating to a “sell (e+)” rating in a research note on Friday, September 4th. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Reduce” and a consensus target price of $73.00.

View Our Latest Research Report on FibroBiologics

About FibroBiologics

(Get Free Report)

FibroBiologics is a clinical-stage biotechnology company developing cell-based therapies for chronic diseases. Its research centers on fibroblasts, cells found in connective tissue that can support tissue repair and other biological processes. The company is developing potential therapies for conditions including multiple sclerosis, degenerative disc disease, wound healing and diabetes. Its programs are investigational, and the company’s approach includes exploring fibroblast cells and related technologies as treatments.

Read More

Earnings History for FibroBiologics (NASDAQ:FBLG)

Receive News & Ratings for FibroBiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroBiologics and related companies with MarketBeat.com's FREE daily email newsletter.